Phaseline

Companies › Aspargo Labs

Aspargo Labs: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Genitourinary.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ASP-001.1 (Hezkue Turbo)
Phosphodiesterase-5 (PDE-5) inhibitor
PDE5APhase 1Erectile Dysfunction–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06872866ASP-001.1 (Hezkue Turbo)Phase 1Erectile DysfunctionGenitourinaryFeb 2026

Targets

PDE5A (1)

Companies with the same targets

Mezzion Pharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.